Use of hormone replacement therapy for correction of high turnover bone disease in hypogonadal β-thalassemia major patients presenting with osteoporosis: Comparison with idiopathic premature ovarian failure

Hemoglobin

Volumn 35, Issue 5-6, 2011, Pages 653-658

  Chatterjee, Ratna ^a   Katz, Maurice ^a   Bajoria, Rekha ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Hormone replacement therapy (HRT); Osteopenia osteoporosis syndrome (OOS); Premature ovarian failure (POF); Thalassemia

Indexed keywords

COLLAGEN TYPE 1; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BETA THALASSEMIA; BONE TURNOVER; COMPARATIVE STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPENIA OSTEOPOROSIS SYNDROME; OSTEOPOROSIS; PATIENT MONITORING; PREMATURE OVARIAN FAILURE; PROSPECTIVE STUDY; SCORING SYSTEM; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPOGONADISM; OSTEOPOROSIS; PRIMARY OVARIAN INSUFFICIENCY; SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81055133465     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.630120     Document Type: Article

References (19)

1. Bajoria R, Chatterjee R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin. 2009;33(1):S136-S138.
2. Weatherall DJ. Pathophysiology of thalassaemia. Bailliére's Clin Haematol. 1998;11(1):127-146. (Pubitemid 29039020)
3. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β-thalassaemia disease. Clin Endocrinol (Oxf). 2003;58(3):273-279. (Pubitemid 36308114)
4. Kalef-Ezra J, Challa A, Chaliasos N, et al. Bone minerals in β-thalassemia minor. Bone. 1995;16(6):651-655.
5. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf). 1995;42(3):279-287.
6. Wonke B, Jensen C, Hanslip JJ, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(suppl. 3):795-801.
7. Chatterton BE, Thomas CM, Schultz CG. Liver density measured by DEXA correlates with serum ferritin in patients with β-thalassemia major. J Clin Densitom. 2003;6(3):283-288. (Pubitemid 37203426)
8. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002;32(7):492-497. (Pubitemid 36067696)
9. Di Stefano M, Chiabotto P, Roggia C, et al. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab. 2004;22(1):53-57. (Pubitemid 38140043)
10. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf). 2000;53(1):33-42. (Pubitemid 30646124)
11. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int. 2004;74(1):68-71. (Pubitemid 38166607)
12. Lasco A, Morabito N, Gaudio A, et al. Osteoporosis and β-thalassemia major: role of the IGFI/ IGFBP-III axis. J Endocrinol Invest. 2002;25(4):338-344. (Pubitemid 34436129)
13. Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of disordered puberty on bone density in β-thalassaemia major. Br J Haematol. 2003;120(2):353-358. (Pubitemid 36194189)
14. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with β-thalassemia major. Osteoporos Int. 2001;12(7):570-575. (Pubitemid 32777434)
15. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 2002,13(8):644-649.
16. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with β-thalassaemia. Br J Haematol. 2003,123(4):730-737. (Pubitemid 37468072)
17. Bajoria R, Sooranna SR, Chatterjee R. Type 1 collagen marker of bone turnover, IGF and leptin in dichorionic twins with discordant birth weight. J Clin Endocrinol Metab. 2006;91(11):4696-4701. (Pubitemid 44833459)
18. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001;86(5):1890-1897. (Pubitemid 32472892)
19. Schnitzer T, Bone HG, Crepaldi G, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000;85(2):720-726. (Pubitemid 32273660)